psychedelics – Page 5

The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses

mycolabadmin

Researchers used computer-based analysis to understand how psilocybin, a compound found in certain mushrooms, might help prevent suicide. They identified four key proteins that psilocybin interacts with and found that it works through serotonin and calcium signaling pathways in the brain, which are known to be involved in depression and suicidal behavior. While these findings are promising, more research is needed to confirm these effects in humans before psilocybin can be used clinically for suicide prevention.

Classic psychedelics do not affect T cell and monocyte immune responses

mycolabadmin

Researchers tested whether common psychedelic drugs (LSD, psilocin, DMT, and mescaline) directly affect human immune cells in laboratory conditions. They found that these psychedelics did not suppress T cell function or immune signaling at the doses tested. This is good news for patients with serious illnesses who might benefit from psychedelic-assisted therapy, as it suggests these treatments won’t dangerously weaken their already compromised immune systems.

Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward

mycolabadmin

Researchers discovered that a single dose of psilocybin can reduce opioid addiction-related behaviors in male mice by activating serotonin receptors in specific brain circuits, but this effect does not work the same way in females. The study reveals that psilocybin changes how the brain processes opioid rewards and withdrawal symptoms, suggesting psychedelics could become a new treatment approach for opioid addiction. However, important sex differences in how the brain responds mean treatments may need to be tailored differently for men and women.

Corrigendum: Ayahuasca-induced personal death experiences: prevalence, characteristics, and impact on attitudes toward death, life, and the environment

mycolabadmin

This article corrects errors in a research study about ayahuasca, a traditional plant medicine. The study examined how experiences with ayahuasca that involve confronting death affect people’s attitudes about mortality, the environment, and life fulfillment. The corrections clarify how often participants used ayahuasca and adjust how the data was visualized in graphs, but the main findings about ayahuasca’s effects remain unchanged.

We need to talk about shrooms

mycolabadmin

The article discusses how psychedelic mushrooms have transformed from being seen as dangerous drugs in the 1960s to being studied as potential psychiatric treatments today. While research shows promise for treating depression, trauma, and addiction, the author warns against oversimplified narratives that ignore important context about how these experiences work and potential risks. The piece calls for careful, balanced discussion about psychedelics that considers both benefits and concerns.

Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects

mycolabadmin

This study directly compared two popular psychedelic drugs, LSD and psilocybin (magic mushrooms), in 28 healthy volunteers. Researchers found that these substances produce very similar mental effects when given at equivalent doses, with the main difference being that LSD lasts longer. The study establishes that about 20 milligrams of psilocybin is roughly equivalent to 100 micrograms of LSD. These findings could help guide dosing for future psychiatric treatments using these psychedelics.

Evaluation of the Indazole Analogs of 5-MeO-DMT and Related Tryptamines as Serotonin Receptor 2 Agonists

mycolabadmin

Researchers synthesized new drug candidates based on psychedelic molecules like 5-MeO-DMT, replacing the indole core with indazole scaffolds to potentially improve drug properties. While the lead compound VU6067416 showed excellent potency for serotonin receptors and favorable pharmacokinetics, it also activated 5-HT2B receptors strongly, raising safety concerns about heart problems. The study highlights the challenge of developing selective serotonin drugs and emphasizes the need for rigorous safety testing of psychedelic-based therapeutics.

Identification of 5-HT2A receptor signaling pathways associated with psychedelic potential

mycolabadmin

Scientists discovered that psychedelic drugs work by activating a specific signaling pathway in the brain called the 5-HT2A-Gq pathway. By creating new drug-like molecules, they found that drugs need to strongly activate this particular pathway to produce psychedelic effects like hallucinations. This discovery could help researchers design new psychiatric medicines that have therapeutic benefits without the hallucinogenic side effects that worry doctors and patients.

Psilocin, LSD, mescaline, and DOB all induce broadband desynchronization of EEG and disconnection in rats with robust translational validity

mycolabadmin

Researchers tested how different psychedelic drugs affect brain electrical activity in rats using EEG recordings. They found that psilocin, LSD, mescaline, and DOB all produced similar patterns of decreased brain activity and reduced communication between brain regions. Importantly, these effects in rats closely matched what scientists observe in human brain studies, suggesting that rats can be useful for understanding how psychedelics work in the brain.

Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression

mycolabadmin

This research study is investigating how psilocybin, a compound from certain mushrooms, affects the brain in people with depression. The study involves 50 participants who will receive either psilocybin or a placebo, with their brain activity monitored using advanced imaging scans. Researchers will examine how psilocybin changes blood flow and network activity in brain regions involved in mood regulation, and whether these changes are linked to improvements in depression symptoms.

Research Topic: psychedelics